Soterix Medical is committed to support activity through the COVID-19 pandemic. Book an online consultation here >> or attend our Webinars here >>
Soterix Medical Inc. (SMI) was formed to develop and deploy innovative medical treatments focused on neuropsychiatric and neurological disorders and rehabilitation. Founded in 2008, SMI is the world leader in clinical trials for non-invasive neuromodulation working with over 450 medical centers in the US and worldwide. SMI has licensed and developed a comprehensive intellectual property portfolio that includes High-Definition transcranial Direct Current Stimulation (HD-tDCS), Limited Total Energy tDCS (LTE-tDCS), and Neurotargeting. From the most targeted non-invasive clinical systems to the most portable units, Soterix Medical provides clinicians and patients with unique and adaptable solutions. Ongoing Phase I, II, IIb, and III trials use investigational devices that are regulated/limited by US or Federal law. SMI is proudly based in New York City with international distributors in all major markets.
At Soterix Medical, Engineering Serving Humanity means that we are committed to bring the most advanced medical technology into the hands of people who need it. The commitment underpins everything we do.
237 W 35 ST,NEW YORK, NY 10001
ISO 13485:2016 certifiedMDSAP certifiedFDA Registered Facility
Advanced clinical and research centers choose Soterix Medical devices and accessories where the highest standards in performance are required. Soterix Medical products stand-out for their usability, unique features, and precision. Leveraging the most advanced scientific understanding, Soterix Medical technology is the standard for neuromodulation clinical trials and human performance testing.
Soterix Medical technologies including but not limited to tDCS-Limited Total Energy (LTE) and High Definiton-tES (HD-tES) is protected by patents, other intellectual property rights, patents pending or other intellectual property rights pending.
Soterix Medical was founded to support the science of non-invasive electrical stimulation. Our stimulation systems are the only technology designed and optimized for advanced and reliable neuromodulation. From exclusive High-Definition systems, Neurotargeting planning software, to the incredibly adaptable 1x1 platform, researchers choose Soterix Medical when stimulation quality cannot be compromised.
Soterix Medical is committed to provide patients and physicians the most advanced, user-friendly, and effective neuromodulation treatments. Our clinical tDCS platforms are the only system to incorporate the latest, most robust technology. Unique electrode and head-gear snap-in technology make consistent and comfortable stimulation “a snap” for patient and care-givers.
Soterix Medical is the leader in transcranial technology. Professionals trust Soterix Medical technology to provide the highest standard of research and clinical grade systems.
Our award-winning customer support team is expert in providing guidance though every administrative process and challenge - from research design support to clinical deployment.
Soterix Medical is driven by the desire to reduce the burden of disease with systems optimized for every individual. In advanced neuromodulation, one size does not fit all.
Soterix Medical Inc. the global leader in non-invasive stimulation and synergistic brain imaging technologies, is pleased to report expanded clinical trials of its proprietary neuromodulation technologies for Alzheimer's disease and Mild Cognitive Impairment.
Learn more about Mini-CT
Learn more about ElectraRx
Soterix Medical Inc. announces it has received FDA Investigational Device Exception (IDE) to launch a trial of transcranial Direct Current Stimulation-Limited Total Energy (tDCS-LTE) neuromodulation at-home for patients with Major Depressive Disorder (MDD).
Learn more about tDCS-LTE
Soterix Medical Inc. he global leader in non-invasive stimulation and synergistic technologies, announced today it has received a 510(k) clearance from U.S. Food & Drug Administration (FDA) for the Neural Navigator system manufactured by Brain Science Tools, Netherlands.
Learn more about the Neural Navigator System
Soterix Medical Inc. announced the launch of its U.S. Food and Drug Administration (FDA) 510k cleared electro-detox™ treatment to reduce opiate and opioid withdrawal symptoms. The electro-detox™ is a battery-powered wearable device placed behind the patient’s ear that emits gentle current pulses to stimulate branches of specific cranial nerves
Learn more about Electro-Detox treatment
Soterix Medical Inc. has been awarded a Phase I NIH-SBIR contract from the National Institute of Drug Abuse (NIDA) of the National Institutes of Health (NIH) for the development of its portable remote-tDCS platform for the treatment of cocaine addiction.
The focus of the project is to develop and validate the first self-administered electrostimulation system to reduce cocaine craving. The stimulation device and protocols developed in this project are further applicable to other addictive substances like nicotine, alcohol, and marijuana and to opioid misuse.
Learn more about Self-Administered Neuromodulation
Soterix Medical Inc. reported positive results from two double-blind, sham-controlled clinical trials of its proprietary transcranial Direct Current Stimulation-Limited Total Energy (tDCS-LTE) technology for the treatment of depression. The Depression tDCS-LTE system is unique in providing drug-free therapy with minimal side effects while maximizing energy delivery to the dorsolateral prefrontal cortex (DLPFC) region, which is implicated in depression control.
The results of the first study “Bipolar Depression Electrical Treatment Trial [BETTER]” were published in JAMA Psychiatry and the results of the second study “ELECT-tDCS” trial were published in New England Journal of Medicine.
Access the First Study
Access the Second Study
Learn more about Depression tDCS-LTE System
Soterix Medical Inc. announced that it has received Singapore’s Health Sciences Authority (HSA) approval for its non-invasive therapeutic medical device. This approval allows Soterix Medical to immediately market its products based on its proprietary transcranial Direct Current Stimulation (tDCS) technology in Singapore. The therapy works by delivering a mild electrical current through electrodes placed on the head relieving the symptom of Major Depression using the Depression tDCS-LTE™ treatment or Fibromyalgia using the PainX™ treatment.
Learn more about Depression tDCS-LTE System
Learn more about PainX System
Soterix Medical Inc. announced it has received a 510(k) clearance from U.S. Food & Drug Administration (FDA) for its IontoDC™ device intended to use a direct current to introduce ions of soluble salts or other drugs into the body.
When the Smithsonian highlighted the most rigorous science around tDCS, they showed Soterix Medical’s exclusive High-Definition tDCS system. Targeted stimulation supporting hypothesis driven research.
Learn about High-Definiton tDCS
Learn about Neurotargeting Software
Al Jazeera America features clinical grade tDCS using industry-standard Soterix Medical technology in adult and pediatric neurorehabilitation*. And an interview with our CTO, Dr. Abhishek Datta.
Industry Standard 1x1 tDCS
For Susceptible Populations 1x1 tDCS-LTE
The Soterix Medical PainX™ tDCS system receives CE Mark for the treatment of Pain including Migraine and Fibromyalgia. Soterix Medical tDCS systems continue to set the standard in research and treatment.
Learn more about PainX™ treatment
The Soterix Medical 1x1 tDCS system receives CE Mark for the treatment of Depression. Medical and research quality tDCS from the trusted leader in transcranial electrical neuromodulation.
Learn about tDCS-LTE Therapy for Depression
Soterix Medical tDCS features on PBS inducing the industry standard 1x1 (start of episode) and our 1x1-LTE, the only device designed for susceptible population (end of episode)
More on Soterix Medical tDCS and LTE™
Motherboard’s lighthearted take on Soterix Medical's exclusive HD-tDCS technology. Learn more about Soterix Medical HD-tDCS for state-of-the-art research and clinical grade neuromodulation.
More on 4x1 HD-tDCS
Brain Targeting Software
Soterix Medical EASYstrap features in Scientific American Mind article on “Your Electric Pharmacy”, the future of tDCS
More on EASYstrap™
Learn more about Home Neuromodulation.
Our exclusive "X configuration" overcomes limitations of conventional tDCS. Soterix HD-tDCS can "penetrate deeper into the brain in more focused areas", reports Nature News.
More on HD-tDCS
Soterix Medical Inc. partners with ElMindA Ltd. to develop a new paradigm for pain control. Visualizing individual pain networks to revolutionalize the targeted treatment of pain - one patient at a time.
Harvard medical school trial
For combining tDCS with monitoring technologies (such as EEG, PET, MEG, Eye-tracking, NIR, fMRI) - Soterix Medical is the only company with the technology and expertise to ensure successful integration.
Contact SMI technical support
WIRED magazine features Soterix medical tDCS and HD-tDCS products in their feature on neuromodulation including our exclusive 4x1 montage for brain targeting”.
Learn more on tDCS
Get started with HD-tDCS
Soterix High-Definition tDCS an "innovation" that "increases the functional resolution" of brain stimulation. Categorical increases in non-invasive targeting with simple to use technology.
Soterix Medical Neurotargeting
Physicians at Harvard Medical School demonstrate the application of tDCS for clinical trial on patients using a Soterix 1x1 device in this Journal of Visualized Experiments video.
Watch the JOVE video
Explore tDCS Devices & Accessories
Soterix EASY-Kits include everything you need for a complete tDCS session in a compact container. Compatible with all Soterix 1x1 Stimulators and Accessories and includes Soterix EASY-Pads.
Learn more about tDCS Accessories
The CT-tDCS platform is the most sophisticated system for clinical trials with tDCS and the only system to provide true double-blind control and online subject monitoring.
Learn more about CT tDCS